All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During Lymphoma Leukemia & Myeloma 2021 Virtual Congress, the Lymphoma Hub was pleased to speak to Robert Gale, Imperial College London, London, UK. We asked, What does ethnogeographic diversity tell us about the cause of chronic lymphocytic leukemia (CLL)?
What does ethnogeographic diversity tell us about the cause of CLL?
Gale begins by contextualizing CLL as a mostly genetic, not radiogenic, cancer and highlighting the significantly lower rates of CLL in individuals of Asian descent. Finally, he explains possible reasons for this genetic difference and outlines current studies investigating single nucleotide variables associated with increased risk of CLL.
FDA clears investigational new drug application for CD20-directed CAR T-cell therapy MB-106
On May 10, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application to evaluate MB-106...
Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?
Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox